Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;87(2):420-429.
doi: 10.1007/s12020-024-04057-y. Epub 2024 Oct 13.

Hypoparathyroidism: an update on new therapeutic approaches

Marco Pitea  1 , Ruggero Lanzafame  1 , Elisa Sala  1 , Ludovica Crocè  1 , Stefano Mora  2   3
Affiliations
Review

Hypoparathyroidism: an update on new therapeutic approaches

Marco Pitea et al. Endocrine. 2025 Feb.

Abstract

Background: Hypoparathyroidism is a rare endocrine disease characterized by insufficient parathyroid hormone (PTH) secretion by the parathyroid glands, leading to hypocalcemia. In contrast to most hormone deficiencies for which hormone replacement is currently the mainstay of therapy, hypoparathyroidism has conventionally been treated with calcium supplements and active analogs of vitamin D. Although the advent of a replacement therapy with 1-34 and 1-84 PTH represented a major step in the therapeutic history of hypoparathyroidism, several new molecules and different management strategies have recently been developed.

Purpose: This review investigates the therapeutic approaches currently under investigation for the treatment of hypoparathyroidism. Clinical trials results have been considered and discussed.

Keywords: Autosomal dominant hypocalcemia; Hypoparathyroidism; Parathyroid hormone; Treatment.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards. Conflict of interest: The authors declare no competing interests. Ethical approval: The manuscript is a review of the literature, and therefore no ethical approval was necessary.

References

    1. B.L. Clarke, E.M. Brown, M.T. Collins, H. Jüppner, P. Lakatos, M.A. Levine, M.M. Mannstadt, J.P. Bilezikian, A.F. Romanischen, R.V. Thakker, Epidemiology and diagnosis of hypoparathyroidism. J. Clin. Endocrinol. Metab. 101, 2284–2299 (2016). https://doi.org/10.1210/jc.2015-3908 - DOI - PubMed - PMC
    1. G. Tuli, R. Buganza, D. Tessaris, S. Einaudi, P. Matarazzo, L. de Sanctis, Teriparatide (rhPTH 1–34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism. Endocrine 67, 457–465 (2020). https://doi.org/10.1007/s12020-019-02128-z - DOI - PubMed
    1. J.P. Bilezikian, Hypoparathyroidism. J. Clin. Endocrinol. Metab. 105, 1722–1736 (2020). https://doi.org/10.1210/clinem/dgaa113 - DOI - PubMed - PMC
    1. M. Mannstadt, L. Cianferotti, R.I. Gafni, F. Giusti, E.H. Kemp, C.A. Koch, K.L. Roszko, L. Yao, G.H. Guyatt, R.V. Yhakker, W. Xia, M.L. Brandi, Hypoparathyroidism: genetics and diagnosis. J. Bone Min. Res. 37, 2615–2629 (2022). https://doi.org/10.1002/jbmr.4667 - DOI
    1. R.I. Gafni, M.T. Collins, Hypoparathyroidism. N. Engl. J. Med. 380, 1738–1747 (2019). https://doi.org/10.1056/NEJMcp1800213 - DOI - PubMed

MeSH terms

LinkOut - more resources